期刊
JOURNAL OF DRUG TARGETING
卷 25, 期 7, 页码 608-615出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/1061186X.2017.1300664
关键词
Diabetes; micropatch; oral insulin delivery; permeation enhancer; proteolytic inhibitor
资金
- National Institutes of Health [R01DK097379]
- University of California, Santa Barbara
- University of California, Office of the President
- MRSEC Program of the National Science Foundation [NSF DMR 1121053]
- NSF
- National Institute of General Medical Sciences of the National Institutes of Health [T34GM113848]
Diabetes mellitus has become a major public health issue that has almost reached epidemic proportions worldwide. Injectable insulin has been typically utilized for the management of this chronic disease. However, lack of patient compliance with injectable formulations has spurred the development of oral insulin formulations, which although appealing, face several delivery challenges. We have developed novel mucoadhesive intestinal patches, several hundred micrometers in dimension (micropatches) that address the challenges of oral insulin delivery. The micropatches adhere to the intestinal mucosa, release their drug load rapidly within 30min and are effective in lowering blood glucose levels in vivo. When insulin-loaded micropatches were administered with a permeation enhancer and protease inhibitor, a peak efficacy of 34% drop in blood glucose levels was observed within 3h. Efficacy further improved to 41% when micropatches were administered in multiple doses. Here, we describe the design of micropatches as an oral insulin formulation and report their in vivo efficacy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据